$4.35
4.82%
Nasdaq, Sep 18, 04:01 pm EDT. Closed.
ISIN
US1856341029
Symbol
CLNN

Clene Inc Stock price

$4.35
+0.26 6.36% 1M
-2.22 33.79% 6M
-1.52 25.89% YTD
-1.97 31.17% 1Y
-6.45 59.73% 3Y
-144.25 97.07% 5Y
-188.65 97.75% 10Y
-188.65 97.75% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
+0.20 4.82%
ISIN
US1856341029
Symbol
CLNN
Industry

Is Clene Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$61.8m
Enterprise Value
$70.9m
Net debt
$9.1m
Cash
$9.7m
Shares outstanding
12.8m
Valuation (TTM | estimate)
P/E
negative
P/S
309.2 | 259.7
EV/Sales
354.4 | 297.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-97.0%
Return on Equity
148.8%
ROCE
-113.0%
ROIC
-
Debt/Equity
-0.8
Financials (TTM | estimate)
Revenue
$200.0k | $238.1k
EBITDA
$-19.1m
EBIT
$-20.6m
Net Income
$-39.5m
Free Cash Flow
$-16.0m
Growth (TTM | estimate)
Revenue
-31.0% | 19.1%
EBITDA
23.6%
EBIT
22.8%
Net Income
-33.0%
Free Cash Flow
9.6%
Margin
Gross
70.1%
EBITDA
-9,704.6%
EBIT
-10,432.0%
Net
-20,059.9%
Free Cash Flow
-8,094.9%
More
EPS
$-3.2
FCF per Share
$-1.2
Short interest
10.0%
Employees
78
Rev per Employee
$0.0

Clene Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Clene Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Clene Inc forecast:

Buy
91%
Hold
9%

Financial data from Clene Inc

Jun '26
+/-
%
0.20 0.20
31% 31%
100%
- Direct Costs 0.06 0.06
0% 0%
30%
0.14 0.14
39% 39%
70%
- Selling and Administrative Expenses 7.79 7.79
32% 32%
3,895%
- Research and Development Expense 20 20
44% 44%
9,840%
-19 -19
24% 24%
-9,560%
- Depreciation and Amortization 1.43 1.43
9% 9%
715%
EBIT (Operating Income) EBIT -21 -21
23% 23%
-10,276%
Net Profit -40 -40
33% 33%
-19,760%

In millions USD.

Don't miss a Thing! We will send you all news about Clene Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clene Inc Stock News

Neutral
GlobeNewsWire
5 days ago
Investment led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene's Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clen...
Neutral
GlobeNewsWire
about one month ago
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided rec...
Neutral
GlobeNewsWire
4 months ago
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an o versubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory m...
More Clene Inc News

Company Profile

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mr. Etherington
Employees 78
Founded 2013
Website clene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today